Quarterly ResultMay 6, 2026, 06:14 AM
BeOne Medicines Q1 Revenue $1.51B, Net Income $227.36M
AI Summary
BeOne Medicines Ltd. reported a significant increase in its first quarter 2026 financial results, with total revenues rising to $1.51 billion and net income surging to $227.36 million. The company also saw a substantial improvement in its gross profit and income from operations compared to the same period last year. Cash and cash equivalents also increased, reflecting a strong financial position.
Key Highlights
- Q1 2026 Total Revenues increased 35.5% to $1.51 billion from $1.12 billion year-over-year.
- Q1 2026 Net Income surged to $227.36 million from $1.27 million year-over-year.
- Basic Earnings Per Share (EPS) rose to $0.16 in Q1 2026 from $0.00 in Q1 2025.
- Gross profit increased 41.4% to $1.35 billion in Q1 2026 from $952.28 million year-over-year.
- Income from operations grew significantly to $249.90 million in Q1 2026 from $11.10 million year-over-year.
- Cash and cash equivalents increased to $4.79 billion as of March 31, 2026, from $4.55 billion at year-end 2025.
- Amgen royalty revenue more than tripled to $18.30 million in Q1 2026 from $5.52 million year-over-year.
- Research and development expenses increased 12.3% to $541.22 million in Q1 2026.